Modell för strukturerad introduktion av nya läkemedel: Syftet är att erbjuda alla patienter ändamålsenlig behandling

Lakartidningen

Volumn 105, Issue 42, 2008, Pages 2917-2922

  Gustafsson, Lars L ^a,b,c   Wettermark, Björn ^a,b,c   Kalin, Mats ^a,c   Korkmaz, Seher ^a,b,d   Persson, Marie E ^b,e   Almkvist, Henrik ^a,b   Hjemdahl, Paul ^a,c   Julander, Margaretha ^a,b   Kristianson, Krister ^c   Ringertz, Bo ^a   Bergendahl, Gunilla Thörnwall ^b   Wilking, Nils ^a,d  

^a Stockholms Läns Landsting ^*

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Apoteket AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SCREENING; ECONOMICS; FORECASTING; HEALTH CARE QUALITY; HUMAN; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; METHODOLOGY; POSTMARKETING SURVEILLANCE; SAFETY; STANDARD;

BIOMEDICAL RESEARCH; COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COSTS; DRUG DISCOVERY; DRUG EVALUATION; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; FORECASTING; HUMANS; INTERNATIONAL COOPERATION; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY ASSURANCE, HEALTH CARE; SAFETY;

EID: 56649112608     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Drews J. Drug discovery: a historical perspective. Science. 2000;287:1960-4.
2. WHO. Priority Medicines for Europe and the World Project. A public health approach to innovation. Geneva: WHO; 2004. Final report nov 2004 [cited 2008 Aug 31]. http://mednet3.who.int/prioritymeds/report/index.html
3. Evans WA, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464-8.
4. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. 2007;81:807-16.
5. Strandberg K. Nya läkemedel 2004-2008: utvecklingstendenser. Personlig information; 2008.
6. Degos L, Romaneix F, Michel P, Bacou J. Can France keep its patients happy? BMJ. 2008;336:254-7.
7. Ny läkemedelsstrategi: Landstinget tar ett samlat grepp om läkemedlen (2003-04-23) [cited 2008 Aug 31]. http://www.janusinfo.se/imcms/ servlet/GetDoc?meta_id=1077
8. Henriksson F, Hjortsberg C, Rehnberg C. Pharmaceutical expenditure in Sweden. Health Policy. 1999;47:125-44.
9. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele' V. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26:537-50.
10. Läksaks lista över definierade specialläkemedel inom Stockholms läns landsting från 2005 och förslag till reviderad lista för 2008 [cited 2008 Aug 31]. http://www.janusinfo.se/imcms/servlet/ GetDoc?meta_id=10405
11. Packer C. The National Horizon Scanning Centre (NHSC): early warning for new and emerging health technologies in England. Evidence-Based Healthcare & Public Health. 2005;9:410-3.
12. Kalin M, Korkmaz S, Persson M, Wettermark B, Wilking N. Prognos över kostnadsutvecklingen för läkemedel i SLL 2008-2009. Läksak, Stockholms läns landsting; 2008 [cited 2008 Aug 31]. http://www.janusinfo. se
13. Wild C, Langer T. Emerging health technologies: informing and supporting health policy early. Health Policy. Epub 2008 Feb 22.
14. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish prescribed drug registry - opportunities for pharmaco epidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726-35.
15. Lundin D, Carlsson P, Levin LÅ, Persson U. Läkemedelsfö rmånsnämndens riktlinjer för hälsoekonomiska utvärderingar. Analys av kostnadseffektivitet i samhällsekonomiskt perspektiv. Läkartidningen. 2006;103:3716-8.
16. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis. 2006;65:707-12.
17. Kalin M, Korkmaz S, Persson M, Wettermark B. Prognos över kostnadsutvecklingen för läkemedel i SLL 2007-2008. Läksak, Stockholms läns landsting; 2007 [cited 2008 Aug 31]. http://www.janusinfo. se
18. Gerdtham UG, Lundin D. Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics. 2004;22:29-42.
19. Jack A. Balancing big pharma's books. BMJ. 2008;336:418-9
20. Garattini S, Bertele' V, Godman B, Haycox A, Wettermark B, Gustafsson LL; The Piperska Group. Enhancing the rational use of new medi cines across European health care systems. Eur J Clin Pharmacol. Epub 2008 Aug 8.